Abstract
The field of pharmaceutical science is a dynamic landscape driven by the pursuit of enhanced drug formulations and improved therapeutic outcomes. One remarkable journey within this domain is the polymorphism odyssey of rivaroxaban, a distinguished anticoagulant inhibitor targeting blood coagulation factor Xa. Rivaroxaban plays a key role in the prevention and treatment of thromboembolic disorders, including myocardial infarction, stroke, and deep venous thromboses. Its intricate crystal structures and diverse solid-state forms, each imparting unique properties affecting solubility, bioavailability, and stability, illuminate the challenges, breakthroughs, and relentless pursuit of superior drug performance in the pharmaceutical development of rivaroxaban. This work not only reflects the scientific commitment to enhancing therapeutic efficacy but also underscores the dynamic interplay between chemical innovation and clinical application in drug development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
